Below are some of the key findings from this Prader-Willi syndrome therapeutics market analysis report
See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.
Get a FREE sample now!
Global Prader-Willi syndrome therapeutics market outlook
Prader-Willi syndrome is rare, and its prevalence rate is usually lower compared with other mainstream indications such as hypertension and diabetes. Regulatory bodies grant special drug designations, such as orphan drug and fast track designations which support the further development of therapeutics for the Prader-Willi syndrome treatment. These increasing number of special drug designations from regulatory bodies is expected to drive the market at a CAGR of close to 5% between 2018-2022.
Leading companies in the global Prader-Willi syndrome therapeutics market
The global Prader-Willi syndrome therapeutics market is dominated by the Americas regarding incremental growth when compared to EMEA and APAC. To help clients improve their revenue shares in this market, this research report provides an analysis of the market's competitive landscape and offers information on the products offered by various leading companies. Additionally, this Prader-Willi syndrome therapeutics market analysis report suggests strategies companies can follow and recommends key areas they should focus on, to make the most of upcoming growth opportunities.
The report offers a detailed analysis of several leading companies, including:
- Eli Lilly
- Novartis
- Novo Nordisk
- Pfizer
Prader-Willi syndrome therapeutics market segmentation based on products
- Recombinant growth hormones
- Others
Recombinant growth hormones was the dominant product of the global Prader-Willi syndrome therapeutics market in 2017. Although the market share of this segment is expected to decrease, it will continue to dominate the market throughout the next five years.
Prader-Willi syndrome therapeutics market segmentation based on region
The Americas accounted for the largest share of the Prader-Willi syndrome therapeutics market share in 2017. The dominance of the Americas can be attributed to the special drug designations for Prader-Willi syndrome treatment and strong drug pipeline for the Prader-Willi syndrome treatment.
Key highlights of the global Prader-Willi syndrome therapeutics market for the forecast years 2018-2022:
- CAGR of the market during the forecast period 2018-2022
- Detailed information on factors that will accelerate the growth of the Prader-Willi syndrome therapeutics market during the next five years
- Precise estimation of the global Prader-Willi syndrome therapeutics market size and its contribution to the parent market
- Accurate predictions on upcoming trends and changes in consumer behavior
- The growth of the Prader-Willi syndrome therapeutics across the Americas, APAC, and EMEA
- A thorough analysis of the market's competitive landscape and detailed information on several vendors
- Comprehensive details on factors that will challenge the growth of Prader-Willi syndrome therapeutics companies
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 05: MARKET SIZING
- Market definition
- Market sizing 2017
- Market size and forecast
PART 06: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 07: PIPELINE LANDSCAPE
PART 08: MARKET SEGMENTATION BY PRODUCT
- Segmentation by product
- Comparison by product
- Recombinant growth hormones – Market size and forecast 2017-2022
- Others – Market size and forecast 2017-2022
- Market opportunity by product
- CUSTOMER LANDSCAPE
PART 09: REGIONAL LANDSCAPE
- Geographical segmentation
- Regional comparison
- Americas – Market size and forecast 2017-2022
- EMEA – Market size and forecast 2017-2022
- APAC – Market size and forecast 2017-2022
- Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 12: MARKET TRENDS
- Strong pipeline
- Increasing strategic alliances
- Use of advanced technologies for diagnosis and treatment of PWS
PART 13: VENDOR LANDSCAPE
- Overview
- Landscape disruption
PART 14: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Eli Lilly and Company
- Novartis
- Novo Nordisk
- Pfizer
PART 15: APPENDIX